Ridaforolimus: Encouraging Activity but Significant ToxicityAdis International Limited (now part of Wolters Kluwer Health)2015PDF165 KB
Vorinostat Synergizes with Ridaforolimus and Abrogates the Ridaforolimus-induced Activation of AKT in Synovial Sarcoma CellsMorgan · BioMed Central2014PDF402 KB
A Randomized Phase II Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared with Ridaforolimus and Exemestane in Patients with Advanced Breast CancerRugo · Breast Cancer Research and Treatment2017PDF454 KB
Phase IB Study of the mTOR Inhibitor Ridaforolimus With CapecitabinePerotti · American Society of Clinical Oncology2010PDF275 KB
Ridaforolimus in Advanced Sarcomas: A Leap Forward or Missed Opportunity?Garrido-Laguna · American Society of Clinical Oncology2012PDF57 KB
The Minimal Impact of Food on the Pharmacokinetics of RidaforolimusStroh · Cancer Chemotherapy and Pharmacology2012PDF228 KB
Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary StentsKonigstein · American College of Cardiology2020PDF749 KB
